Stock Events

Stock Events

OKYO Pharma Limited 

$0.013700
23
-$0.01-32.51% Friday 19:39

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
19.39M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

31MarExpected
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
-0
-0
-0
0
Expected EPS
0
Actual EPS
-0.0021

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. competes in the biopharmaceutical sector focusing on ophthalmology among other areas, directly competing with OKYO's eye disease treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, through its ophthalmology division, competes in developing treatments for eye diseases, similar to OKYO Pharma's focus.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. has a strong presence in the pharmaceuticals market, including treatments for eye conditions that compete with OKYO's product pipeline.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies Inc., through its eye health products, competes directly with OKYO Pharma in the ophthalmology market.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, positioning it as a competitor to OKYO Pharma's eye disease treatments.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. has investments in therapies for neurological conditions, some of which include ophthalmologic applications, indirectly competing with OKYO.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is broadly in the biopharmaceutical field with a focus on viral diseases but its expansion into other areas can position it as a competitor to OKYO.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a diverse pharmaceutical portfolio, including investments in treatments for eye diseases, making it a potential competitor to OKYO Pharma.

About

Financial Conglomerates
Finance
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Show more...
CEO
Robert J. Dempsey
Employees
5
Country
United Kingdom
ISIN
GG00BD3FV870
WKN
000A2JQ3D

Listings

MU
DE
OK10.MU
STU
DE
OK1.STU
MU
DE
OK11.MU
STU
DE
OK10.STU

0 Comments

Share your thoughts

FAQ

What is OKYO Pharma Limited stock price today?▼
The current price of EMMLF is $0.01 USD — it has decreased by -32.51% in the past 24 hours. Watch OKYO Pharma Limited stock price performance more closely on the chart.
What is OKYO Pharma Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange OKYO Pharma Limited stocks are traded under the ticker EMMLF.
What is OKYO Pharma Limited market cap?▼
Today OKYO Pharma Limited has the market capitalization of 19.39M
What were OKYO Pharma Limited earnings last quarter?▼
EMMLF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does OKYO Pharma Limited have?▼
As of September 04, 2026, the company has 5 employees.
In which sector is OKYO Pharma Limited located?▼
OKYO Pharma Limited operates in the Health & Wellness sector.
When did OKYO Pharma Limited complete a stock split?▼
The last stock split for OKYO Pharma Limited was on May 22, 2023 with a ratio of 1:65.
Where is OKYO Pharma Limited headquartered?▼
OKYO Pharma Limited is headquartered in London, United Kingdom.